NK News and Press, NantKwest From 01/19/21

The South Africa Health Products Regulatory Authority has signed-off ImmunityBio's Phase 1 trial to evaluate its hAd5 T-cell vaccine, the company’s COVID-19 vaccine candidate.The same vaccine is currently being tested in a similar Phase 1 trial in the U.S., with no safety con...

After a ~9.9% rise in value yesterday, Sorrento Therapeutics (SRNE) has added another ~8.9% so far today, and an analyst from H.C. Wainwright estimates a price target of ~$30 for the stock, implying a ~275.0% upside to yesterday’s close.The analyst Ram Selvaraju pro...

NantKwest and ImmunityBio announced they are preparing to merge to create a juggernaut immunotherapy and cell therapy company. Now, NantKwest investors will have ownership of ImmunityBio's impressive pipeline. As the COVID-19 pandemic accelerates and new variants emerge, health agenci...

Gainers: Organogenesis Holdings (ORGO) +33%. Lexicon Pharmaceuticals (LXRX) +30%. NantKwest (NK) +27%. Oragenics (OGEN) +25%. Bicycle Therapeutics (BCYC) +23%.Losers: Viveve Medical (VIVE) -23%. Cassava Sciences (SAVA) -12%. Timber Pharmaceuticals (TMBR) -11%. InflaRx N.V. (IFRX) -9...

NantKwest (NK) has climbed 36.2% in premarket trading as Piper Sandler reiterates its overweight rating on the company after yesterday’s announcement of the early interim results yesterday for survival rates in metastatic pancreatic cancer trials.With a primary endpoint of ov...

Express (EXPR) +62% as company lines up new financing.DPW Holdings (DPW) +57% as pre-orders for residential level 2 EV chargers have begun on Amazon.Pingtan Marine Enterprise (PME) +43% on announcing FY 2021 guidance.ZW Data Action Technologies (CNET) +38%. after the company wa...

NantKwest (NK) +22.7% post-market after saying early interim results of its PD-L1 t-haNK protocols showed median survival rates more than doubled the historic rate in patients with advanced metastatic pancreatic cancer for which no other FDA-approved treatment exists.The company says the tria...

Pivotal QUILT 88 trial based on combination immunotherapy of “Cancer Moonshot” strategy; early indications of increased survival rate for pancreatic cancer patients with no other approved treatment options In initial Cancer Moonshot QUILT trials of haNK and avelu...

NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Dr. Patrick Soon-Shiong M.D., Executive Chairman of the Board of Directors, will participate in the 39 th Annual J.P. Morgan Healthcare Conference. He will make a for...

NEW YORK, NY / ACCESSWIRE / December 30, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: NantKwest, Inc. (NASDAQ: NK ) relating to i...